"The benefit-harm profiles of new medicines are usually not fully known at the time of regulatory approval" > Think about that for a moment...http://blogs.bmj.com/bmjebmspotlight/2017/11/14/rare-adverse-events-clinical-trials-understanding-rule-three/?utm_content=buffer503ca&utm_medium=social&utm_source=twitter.com&utm_campaign=buffer …
-
Show this thread
"...most trials are powered to detect benefits but not adverse events and also because adverse events are selectively reported or misinterpreted." In other words, YOU are the real guinea pigs.
0 replies
1 retweet
1 like
Loading seems to be taking a while.
Twitter may be over capacity or experiencing a momentary hiccup. Try again or visit Twitter Status for more information.